Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChristopher J. Sweeney, Robert S. DiPaola, Joel Picus et al.|New England Journal of Medicine|2015Cited by 2.8k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos E. Kyriakopoulos, Christopher J. Sweeney, Yu‐Hui Chen et al.|Journal of Clinical Oncology|2018Cited by 1.1k
Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyPhilip W. Kantoff, Nicholas J. Vogelzang, Susan Halabi et al.|Journal of Clinical Oncology|1999Cited by 893
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)Hedy L. Kindler, Richard M. Goldberg, Donna Niedzwiecki et al.|Journal of Clinical Oncology|2010Cited by 840
Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583)Eric J. Small, Nicholas J. Vogelzang, Susan Halabi et al.|Journal of Clinical Oncology|2004Cited by 502